TRU 015

Drug Profile

TRU 015

Alternative Names: PF-5212374; TRU-015

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Trubion Pharmaceuticals
  • Developer Pfizer; Trubion Pharmaceuticals; Wyeth
  • Class Antineoplastics; Antirheumatics; Peptides
  • Mechanism of Action Apoptosis stimulants; B cell inhibitors; CD20 antigen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Non-Hodgkin's lymphoma; Rheumatoid arthritis

Most Recent Events

  • 15 Jun 2010 Discontinued - Phase-II for Rheumatoid arthritis in Canada (IV)
  • 15 Jun 2010 Discontinued - Phase-II for Rheumatoid arthritis in European Union (IV)
  • 15 Jun 2010 Discontinued - Phase-II for Rheumatoid arthritis in Mexico (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top